The Supreme Court today (May 13) dismissed the plea filed by the Competition Commission of India (CCI) challenging a glass ...

The latest portfolio update by Kotak Institutional Equities enhances allocations for InterGlobe Aviation and Pidilite, ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

The Indian stock markets ended lower on Tuesday as investors booked profits following Monday’s sharp rally. The sell-off was ...

For the year so far, FIIs have been net sellers of shares worth Rs 1.25 lakh crore, while DIIs have net bought Rs 2.27 lakh ...

SoftBank's India portfolio includes companies like Zomato-owned Blinkit, Delhivery, Flipkart, Paytm and Policybazaar.

While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

The Indian Pharmaceutical Alliance (IPA) emphasizes the need to balance innovation with affordability in response to ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

The generic medicine industry of India is unlikely to be impacted by United States president Donald Trump's decision to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General ...

Equity benchmarks tumble as IT stocks lead decline despite easing geopolitical tensions, with markets opening lower.